• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-line immune-chemotherapy combination for squamous NSCLC is already a reality.

作者信息

Hendriks Lizza E L, Menis Jessica, Remon Jordi

机构信息

Department of Pulmonary Diseases GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

出版信息

Transl Lung Cancer Res. 2020 Jun;9(3):819-823. doi: 10.21037/tlcr.2020.03.36.

DOI:10.21037/tlcr.2020.03.36
PMID:32676345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7354107/
Abstract
摘要

相似文献

1
First-line immune-chemotherapy combination for squamous NSCLC is already a reality.用于鳞状非小细胞肺癌的一线免疫化疗联合方案已然成为现实。
Transl Lung Cancer Res. 2020 Jun;9(3):819-823. doi: 10.21037/tlcr.2020.03.36.
2
Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.免疫检查点抑制剂联合化疗作为一线治疗非鳞状非小细胞肺癌的疗效和安全性：一项荟萃分析和间接比较。
Ann Palliat Med. 2021 Mar;10(3):2766-2775. doi: 10.21037/apm-20-1498. Epub 2021 Feb 1.
3
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.信迪利单抗与其他 PD-L1 抑制剂用于非鳞状非小细胞肺癌一线治疗的间接比较。
Future Oncol. 2022 May;18(15):1896-1905. doi: 10.2217/fon-2021-1336. Epub 2022 Mar 21.
4
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
5
The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center.贝伐单抗联合化疗用于非鳞状非小细胞肺癌的最佳时机和疗程：来自中国一家癌症中心真实世界经验的启示
Ann Transl Med. 2020 Oct;8(20):1311. doi: 10.21037/atm-20-6327.
6
A Network Meta-Analysis of Cancer Immunotherapies Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression.癌症免疫疗法的网状Meta分析：化疗用于一线治疗非小细胞肺癌且程序性死亡配体1高表达患者
Front Oncol. 2021 Jul 9;11:676732. doi: 10.3389/fonc.2021.676732. eCollection 2021.
7
[Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].[组织学对培美曲塞疗效的影响：中国晚期非小细胞肺癌患者二线应用培美曲塞及一线治疗后维持治疗的情况]
Zhonghua Zhong Liu Za Zhi. 2014 Jan;36(1):29-33.
8
First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.一线 PD-1/PD-L1 抑制剂联合化疗与贝伐珠单抗联合化疗治疗晚期非鳞状非小细胞肺癌的比较：一项随机对照试验的贝叶斯网状荟萃分析。
Cancer Med. 2022 May;11(10):2043-2055. doi: 10.1002/cam4.4589. Epub 2022 Mar 22.
9
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.帕博利珠单抗对比标准治疗化疗用于 PD-L1 阳性（>50%）转移性鳞状和非鳞状非小细胞肺癌一线治疗的成本效果分析。在法国。
Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.
10
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.卡瑞利珠单抗联合卡铂和紫杉醇一线治疗晚期鳞状 NSCLC（CameL-Sq）：一项 3 期试验。
J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16.

引用本文的文献

1
Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy.胚系二氢嘧啶脱氢酶基因变异对接受铂类化疗的不可切除性非小细胞肺癌患者预后的影响。
Int J Mol Sci. 2023 Jun 7;24(12):9843. doi: 10.3390/ijms24129843.

本文引用的文献

1
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.帕博利珠单抗联合铂类化疗治疗 NSCLC 合并稳定脑转移患者的疗效：KEYNOTE-021、-189 和 -407 的汇总分析。
J Thorac Oncol. 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020. Epub 2021 Jul 12.
2
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.阿替利珠单抗联合卡铂和白蛋白紫杉醇治疗晚期鳞状 NSCLC（IMpower131）：一项随机 III 期试验的结果。
J Thorac Oncol. 2020 Aug;15(8):1351-1360. doi: 10.1016/j.jtho.2020.03.028. Epub 2020 Apr 14.
3
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.卡铂紫杉醇或nab-紫杉醇联合或不联合帕博利珠单抗治疗转移性鳞状非小细胞肺癌患者的健康相关生活质量。
J Clin Oncol. 2020 Jan 20;38(3):271-280. doi: 10.1200/JCO.19.01348. Epub 2019 Nov 21.
4
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
5
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.一线帕博利珠单抗治疗 PD-L1 表达非常高的非小细胞肺癌患者的结局。
Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288.
6
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
7
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
8
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.
9
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
10
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.